Free Trial

Organigram (TSE:OGI) Trading Down 0.5% - Here's Why

Organigram logo with Medical background

Key Points

  • Organigram Holdings Inc. shares decreased by 0.5% to C$2.07, with trading volume down 71% from its average.
  • The company has a market cap of C$255.73 million and a negative P/E ratio of -4.38.
  • Organigram specializes in producing indoor-grown cannabis products aimed at both patients and recreational consumers.
  • Interested in Organigram? Here are five stocks we like better.
  • Limited Time Offer: Unlock powerful research tools, advanced financial data, and expert insights to help you invest with confidence. Save 50% when you upgrade to MarketBeat All Access during the month of July. Claim your discount here.

Organigram Holdings Inc. (TSE:OGI - Get Free Report) shares dropped 0.5% during trading on Friday . The stock traded as low as C$2.01 and last traded at C$2.07. Approximately 50,748 shares were traded during mid-day trading, a decline of 71% from the average daily volume of 175,631 shares. The stock had previously closed at C$2.08.

Organigram Stock Down 0.5%

The company has a quick ratio of 2.62, a current ratio of 3.36 and a debt-to-equity ratio of 3.07. The company has a market cap of C$255.73 million, a P/E ratio of -4.38, a price-to-earnings-growth ratio of 0.42 and a beta of 1.13. The company has a fifty day moving average of C$1.91 and a 200 day moving average of C$1.80.

About Organigram

(Get Free Report)

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Organigram Right Now?

Before you consider Organigram, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.

While Organigram currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines